Compare Stocks: ARMP, CTMX, CBIO, and ALLO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.73 +2.4%	$1.92	$1.04 ▼ $4.46	$583.88M	0.47	4.86 million shs	3.95 million shs
ARMP Armata Pharmaceuticals	$4.10 +0.7%	$4.88	$2.92 ▼ $16.34	$151.33M	1.34	353,460 shs	253,293 shs
CBIO Crescent Biopharma	$16.77 -2.4%	$17.12	$8.72 ▼ $27.41	$638.13M	1.24	295,307 shs	665,896 shs
CTMX CytomX Therapeutics	$2.82 +1.8%	$3.39	$1.94 ▼ $8.21	$602.49M	2.14	3.56 million shs	4.21 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+2.37%	-1.70%	-14.78%	-13.50%	+53.10%
ARMP Armata Pharmaceuticals	+0.74%	-21.61%	-10.09%	-42.09%	+38.51%
CBIO Crescent Biopharma	-2.39%	-13.82%	+0.48%	-5.20%	+31.02%
CTMX CytomX Therapeutics	+1.81%	-15.82%	-16.81%	-4.41%	+46.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.73 +2.4%	$1.92	$1.04 ▼ $4.46	$583.88M	0.47	4.86 million shs	3.95 million shs
ARMP Armata Pharmaceuticals	$4.10 +0.7%	$4.88	$2.92 ▼ $16.34	$151.33M	1.34	353,460 shs	253,293 shs
CBIO Crescent Biopharma	$16.77 -2.4%	$17.12	$8.72 ▼ $27.41	$638.13M	1.24	295,307 shs	665,896 shs
CTMX CytomX Therapeutics	$2.82 +1.8%	$3.39	$1.94 ▼ $8.21	$602.49M	2.14	3.56 million shs	4.21 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	+2.37%	-1.70%	-14.78%	-13.50%	+53.10%
ARMP Armata Pharmaceuticals	+0.74%	-21.61%	-10.09%	-42.09%	+38.51%
CBIO Crescent Biopharma	-2.39%	-13.82%	+0.48%	-5.20%	+31.02%
CTMX CytomX Therapeutics	+1.81%	-15.82%	-16.81%	-4.41%	+46.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	379.77% Upside
ARMP Armata Pharmaceuticals	2.67	Moderate Buy	$15.00	265.85% Upside
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	76.51% Upside
CTMX CytomX Therapeutics	2.83	Moderate Buy	$11.90	321.99% Upside

Current Analyst Ratings Breakdown

Latest ARMP, CTMX, CBIO, and ALLO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
9/11/2026	CTMX CytomX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
9/9/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	CBIO Crescent Biopharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/19/2026	CTMX CytomX Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$6.00
8/13/2026	CTMX CytomX Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$12.00 ➝ $11.00
8/12/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	CTMX CytomX Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$15.00 ➝ $14.00

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$4.64M	128.81	N/A	N/A	$1.30 per share	1.33
ARMP Armata Pharmaceuticals	$4.90M	31.11	N/A	N/A	($6.00) per share	-0.68
CBIO Crescent Biopharma	$11.88M	52.42	N/A	N/A	$14.32 per share	1.17
CTMX CytomX Therapeutics	$76.20M	8.06	N/A	N/A	$0.58 per share	4.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
ARMP Armata Pharmaceuticals	-$173.80M	-$1.64	N/A	N/A	N/A	-3,467.04%	-12.24%	32.16%	11/11/2026 (Estimated)
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
CTMX CytomX Therapeutics	-$17.37M	-$0.50	N/A	N/A	N/A	-435.21%	-38.46%	-30.33%	11/5/2026 (Estimated)

Latest ARMP, CTMX, CBIO, and ALLO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/12/2026	Q2 2026	ARMP Armata Pharmaceuticals	-$0.4450	-$0.27	+$0.1750	-$0.27	$0.40 million	$2.51 million
8/6/2026	Q2 2026	CTMX CytomX Therapeutics	-$0.0771	-$0.09	-$0.0129	-$0.09	$12.39 million	$1.42 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ARMP Armata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	10.72	10.72
ARMP Armata Pharmaceuticals	N/A	0.11	0.11
CBIO Crescent Biopharma	N/A	9.66	9.66
CTMX CytomX Therapeutics	N/A	9.36	9.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ARMP Armata Pharmaceuticals	3.57%
CBIO Crescent Biopharma	75.19%
CTMX CytomX Therapeutics	67.77%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
ARMP Armata Pharmaceuticals	84.50%
CBIO Crescent Biopharma	24.84%
CTMX CytomX Therapeutics	3.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	152	345.49 million	299.89 million	Optionable
ARMP Armata Pharmaceuticals	61	37.18 million	5.76 million	Not Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
CTMX CytomX Therapeutics	69	217.90 million	209.62 million	Optionable

ARMP, CTMX, CBIO, and ALLO Headlines

Recent News About These Companies

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Up 6.1% - Still a Buy?

September 16 at 12:39 PM | marketbeat.com

CytomX Therapeutics (NASDAQ:CTMX) Shares Down 8.6% - Here's Why

September 15 at 12:59 PM | marketbeat.com

CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow

September 10, 2026 | seekingalpha.com

684,539 Shares in CytomX Therapeutics, Inc. $CTMX Bought by Bank of New York Mellon Corp

September 8, 2026 | marketbeat.com

CytomX Therapeutics, Inc. $CTMX Shares Purchased by Wellington Management Group LLP

September 7, 2026 | marketbeat.com

CytomX Therapeutics, Inc. $CTMX Stake Lowered by Velan Capital Investment Management LP

September 3, 2026 | marketbeat.com

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by Analysts

September 2, 2026 | marketbeat.com

CytomX Therapeutics (NASDAQ:CTMX) Trading Up 6.7% - Time to Buy?

September 1, 2026 | marketbeat.com

CytomX Therapeutics to Present at Upcoming September Investor Conferences

September 1, 2026 | globenewswire.com

BlackRock Inc. Makes New $65.85 Million Investment in CytomX Therapeutics, Inc. $CTMX

August 31, 2026 | marketbeat.com

Deutsche Bank AG Makes New $2.49 Million Investment in CytomX Therapeutics, Inc. $CTMX

August 28, 2026 | marketbeat.com

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

August 27, 2026 | manilatimes.netM

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

August 27, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/08/27/3351944/37704/en/cytomx-therapeutics-announces-fda-fast-track-designation-for-varsetatug-masetecan-varseta-m-for-relapsed-refractory-metastatic-colorectal-cancer-r-r-mcrc.html$

Seven Fleet Capital Management LP Makes New $4.07 Billion Investment in CytomX Therapeutics, Inc. $CTMX

August 27, 2026 | marketbeat.com

Elmind Capital LP Buys New Stake in CytomX Therapeutics, Inc. $CTMX

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys New Shares in CytomX Therapeutics, Inc. $CTMX

August 26, 2026 | marketbeat.com

CytomX Therapeutics (NASDAQ:CTMX) Rating Lowered to Sell at Wall Street Zen

August 23, 2026 | marketbeat.com

CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research

August 21, 2026 | marketbeat.com

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway

August 12, 2026 | seekingalpha.com

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARMP, CTMX, CBIO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.73 +0.04 (+2.37%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$1.74 +0.01 (+0.52%)

As of 04:52 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Armata Pharmaceuticals NYSEAMERICAN:ARMP

$4.10 +0.03 (+0.74%)

Closing price 09/17/2026 04:10 PM Eastern

Extended Trading

$4.17 +0.07 (+1.71%)

As of 05:49 AM Eastern

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.

Crescent Biopharma NASDAQ:CBIO

$16.77 -0.41 (-2.39%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$16.74 -0.04 (-0.21%)

As of 09/17/2026 04:10 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

CytomX Therapeutics NASDAQ:CTMX

$2.82 +0.05 (+1.81%)

Closing price 09/17/2026 04:00 PM Eastern

Extended Trading

$2.82 +0.00 (+0.11%)

As of 05:00 AM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARMP, CTMX, CBIO, and ALLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARMP, CTMX, CBIO, and ALLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARMP, CTMX, CBIO, and ALLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARMP, CTMX, CBIO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Armata Pharmaceuticals NYSEAMERICAN:ARMP

Crescent Biopharma NASDAQ:CBIO

CytomX Therapeutics NASDAQ:CTMX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARMP, CTMX, CBIO, and ALLO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARMP, CTMX, CBIO, and ALLO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARMP, CTMX, CBIO, and ALLO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARMP, CTMX, CBIO, and ALLO Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Armata Pharmaceuticals NYSEAMERICAN:ARMP

Crescent Biopharma NASDAQ:CBIO

CytomX Therapeutics NASDAQ:CTMX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools